Media Room
Third Quarter 2025
Third quarter 2025 results were reviewed by management during a live audio webcast with the financial community on October 24, 2025. The presentation was followed by a Q&A session.
Press releases
November 7, 2025
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
October 28, 2025
Press release: Sanofi successfully prices USD 3 billion of bond issue
Contact Our Media Team
You are a journalist and have a question about Sanofi, please contact the Global Media relations team. Please note the contact details are only for journalists.
Publications
Half year 2025 financial report XBRL package
Half Year 2025 Financial Report
Sustainability Statement 2024 (ESG Report)
Registration Document 2024 (in French)